China’s National Medical Products Administration (NMPA) approved Dizal Pharmaceutical Co. Ltd.’s golidocitinib for treating adults with relapsed or refractory peripheral T-cell lymphoma whose disease has progressed or was refractory to at least one prior systemic therapy.
China’s National Medical Products Administration (NMPA) approved Dizal Pharmaceutical Co. Ltd.’s golidocitinib for treating adults with relapsed or refractory peripheral T-cell lymphoma whose disease has progressed or was refractory to at least one prior systemic therapy.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. has described EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
Half of patients with HER2-positive advanced breast cancer develop metastases in the central nervous system (CNS), even while receiving HER2-directed therapies.
